JMP Securities Reaffirms “Market Outperform” Rating for Kura Oncology (NASDAQ:KURA)

JMP Securities restated their market outperform rating on shares of Kura Oncology (NASDAQ:KURA) in a report issued on Monday morning, Benzinga reports. They currently have a $32.00 price objective on the stock.

Other equities research analysts have also recently issued reports about the stock. HC Wainwright reissued a buy rating and issued a $32.00 price objective on shares of Kura Oncology in a research note on Friday, May 3rd. Wedbush restated an outperform rating and set a $37.00 price objective on shares of Kura Oncology in a research report on Friday, May 3rd. Finally, StockNews.com downgraded shares of Kura Oncology from a hold rating to a sell rating in a report on Monday, April 15th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of Moderate Buy and an average price target of $28.28.

Kura Oncology Price Performance

Shares of KURA opened at $20.55 on Monday. The company has a current ratio of 16.67, a quick ratio of 16.67 and a debt-to-equity ratio of 0.02. The stock’s 50 day moving average is $20.63 and its two-hundred day moving average is $16.25. Kura Oncology has a twelve month low of $7.41 and a twelve month high of $24.17. The firm has a market capitalization of $1.57 billion, a PE ratio of -9.47 and a beta of 0.89.

Kura Oncology (NASDAQ:KURA) last released its quarterly earnings data on Thursday, May 2nd. The company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by ($0.03). The company’s revenue was up .0% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.50) earnings per share. Research analysts anticipate that Kura Oncology will post -2.35 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of KURA. Signaturefd LLC lifted its holdings in shares of Kura Oncology by 40.4% during the 4th quarter. Signaturefd LLC now owns 5,038 shares of the company’s stock valued at $72,000 after acquiring an additional 1,449 shares in the last quarter. SG Americas Securities LLC acquired a new stake in shares of Kura Oncology in the first quarter valued at about $110,000. China Universal Asset Management Co. Ltd. raised its holdings in shares of Kura Oncology by 352.6% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,590 shares of the company’s stock valued at $124,000 after buying an additional 6,692 shares during the period. Saxon Interests Inc. acquired a new position in Kura Oncology during the 1st quarter worth approximately $201,000. Finally, Pale Fire Capital SE purchased a new position in Kura Oncology in the 3rd quarter worth approximately $92,000.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.